January 22, 2018
Strategically expansion of pharmaceutical consulting services in China
EPS International Holdings Co., Ltd. (HQ: Shinjuku, Tokyo; Representative Director & President: Hisashi Tanaka; "EPSI" hereafter) has announced today that it has reached an agreement on a strategic partnership with 北京格鋭博医薬研発有限公司 (G&P) (HQ: Dongcheng, Beijing; Representative Director: 郝 冰; "G&P" hereafter) in order to provide pharmaceutical consulting services in China.
The massive Chinese medical and pharmaceutical products market (second in size only to the US market) is expected to continue to develop rapidly with an initiative announced by local authorities to reform its review and approval systems. Service providers who offer comprehensive support in developing medical and pharmaceutical products will play an increasingly important role. It is especially valuable to have such a provider specialized in strategic pharmaceutical regulatory services.
G&P employees, many of whom having worked for local Chinese subsidiaries of Japanese pharmaceutical companies, are well-versed in planning medical and pharmaceutical product development, and in regulatory submission and registration of pharmaceuticals. The strong relationships they have built with local authorities serve as a definite strength in the market.
The EPS Group first entered the Chinese market in 2001, and since then has provided customers with a range of services as one of first Japanese CROs. This partnership will enable EPSI to build an organization capable of providing even more advanced services to customers in Japan and oversees, as a total service provider in China.
EPSI will continue to focus on creating new services under the corporate philosophy of the EPS Group: "We will contribute to the advancement of the healthcare industry by providing high-value-added solutions to our clients."
For inquiries related to this news release:
EPS International Holdings Co., Ltd.
Management HQ (PR) Takihiro Hirasawa